ASCO Annual Meeting, Chicago

May 30, 2014 | Investor

Bavarian Nordic was present at the conference with an exhibit on PROSTVAC and the PROSPECT clinical trial - a global, randomized, double-blind, placebo-controlled Phase 3 study of PROSTVAC® in men with asymptomatic and minimally symptomatic metastatic, castration-resistant prostate cancer.

The Company also hosted a PROSTVAC update and reception for members of the investment community on Saturday, May 31, 2014 in Chicago, IL at 5 PM CDT.